I updated the company's website. Now that it aims to become a global company, it is basically made to have an English homepage. Although I haven't included all the business details on the website yet, 3BIGS is doing a variety of things from building bio-big data platforms to customization consulting and discovering new drug candidates. Come visit us. https://3bigs.com/
3BIGS CO., LTD.’s Post
More Relevant Posts
-
Everyone knows that India is a fairly good country in IT. It is also called India's Silicon Valley, and "Bangalore" is home to 35% of India's IT professionals. That's why 3BIGS has been the first and only Korean company in the bio sector to establish and operate a branch in Bangalore since 2018. Through a visit to Garden City University in February, I learned that the old name of the city is Garden City. Yesterday, I signed an MOU with Garden City University. After visiting in February to introduce and present the company, the students are interning at 3BIGS, and they are doing so well. Among the tens of thousands of cities in the world, Bangalore is one of the 10 most rapidly growing cities in the world. In other words, Garden City University will also increase its status considerably in the future. Based on this MOU, there will be more diverse and closer cooperation between Garden City University and 3BIGS. Since the university is located in the same city, there are quite a lot of areas to cooperate. As I visited in February, I was so moved that I made Korean food and served it to a hotel restaurant run by the school as a Korean. I attended with Indian executives and team leaders who have been working together for 7 years since 2018 and shared their vision for 3BIGS. I have focused on overseas business such as Middle Eastern countries since last year, but I think I will see results one by one starting this month. Soon, you will see the 2nd round of 3BIGS.
-
-
-
-
-
+2
-
-
It's been a long time since I posted this. It feels like I have to go abroad to talk about it. I was appointed as an adjunct professor at Manipal University in India in May this year, and I was selected as the first key note speaker at an international conference held today at Manipal University, and I made a presentation titled "BioAI based FemTech Platform." 50% of the world's 8 billion people are women. I presented 3BIGS's business model for health care solutions and platforms for women. In India, the largest market in the future, I'm now going to approach it as a research-based business model. I think India is a lot friendlier now.
-
-
3BIGS’ cosmetic peptide sets foot. An atopic lesion improving peptide can now be used in cosmetic formulation to heal skin injury and as skin protection. This is achieved by the gain of INCI name (International Nomenclature Cosmetic Ingredient) and its registration in International Cosmetic Ingredient Dictionary and Handbook. INCI names are internationally recognized systematic nomenclature to identify cosmetic ingredients. It is designated by the International Cosmetic Ingredient Nomenclature Committee (INC) and published by Personal Care Products Council (PCPC). We are happy to get recognition after rigorous screening to ensure the safety and quality of cosmetic peptide. #3BIGS_Cosmetic_Peptide #INCI #INC #PCPC #Atopicpeptide #Skin_peptide
-
-
Crohn’s disease and ulcerative colitis collectively termed inflammatory bowel disease (IBD) is an autoimmune disorder affecting gut health. Although the exact causal factor for the condition is unknown, the mainstay medication relies majorly on immunosuppressants, anti-inflammatory drugs, biologics and steroids to halt/reduce the inflammation and flare ups. 3BIGS is excited to share the identification of anti-inflammatory peptide that targets TNF-α for the treatment of IBD, utilizing its bio big data guided AI pipeline. TNF-α is the main cytokine mediator responsible for the chronic inflammation and tissue damage observed in IBD. TNF targeting biologics revolutionized IBD treatment along with conventional therapy. Peptide drugs has an advantage of lesser production cost, no immunogenicity, more stable molecule than biologics. Promising results from the pre-clinical studies of 3BIGS’ TNF targeting peptide encourage us to move forward to the next phase of peptide drug development. #IBD #colitis #TNFtargetingpeptide #peptidedrug #antiinflammatories #antiTNF #biobigdata #AI
-
-
Porphyromonas gingivalis is a pathogenic gram negative anaerobic bacteria that can colonize in the oral cavity, causing a bacterially induced inflammatory disease defined as periodontal disease. Oral and/or topical antibiotics might be used to control or treat infection in addition to nonsurgical interventions like scaling and root planing. But the overuse or misuse of antibiotics could be attributed to the emergence of antibiotic resistance P. gingivalis strain. To prevent this, 3BIGS Co. Ltd. has successfully identified an antibacterial peptide which has excellent antibacterial activity against P. gingivalis. The invention is patent registered in the Korean Intellectual Property office. The peptide is effective against P. gingivalis at minimal concentration than the regular dose of antibiotics. Notably, the peptide exhibited no cytotoxicity in normal epidermal phenotype present in the oral mucosa at the concentration needed for anti P. gingivalis activity as well as higher concentrations. Taken together, this peptide has good antibacterial activity with no cytotoxicity. Several scientific studies have investigated the link between periodontal disease and Alzheimer’s disease (AD). P. gingivalis, the periodontal pathogens were detected in the AD brain and the chronic inflammatory nature of periodontitis exacerbate the inflammatory process in the AD brain. So, we intend to propose the usage of 3BIGS anti P. gingivalis peptide both in the prevention and treatment of periodontal disease and Alzheimer's disease. Stay connected to #3BIGS to know about the discovery and development of 3BIGS’ antimicrobial peptides. #3BIGS #antibacterialpeptide #Pgingivalis #periodontaldisease #Alzheimers #gingivitis #periodontitis
-
-
I received very good news. I was appointed as an adjunct professor of biotechnology at the Manipal Institute of Technology (MIT), which is more famous for the university that Microsoft CEO Satya Nadella attended. Not only President Satya Nadella but also the graduates of this school have incredible global influence. There are over 1,000 four-year universities in India, ranking sixth among all universities in the country, and the College of Engineering was named the best university in the country. It was my first visit here in May last year, giving special lectures to more than 200 professors and graduate students, and signing an MOU in October. It is an honor for my family to be appointed as an adjunct professor. I will try to show the best in my field to global talents.
-
-
-
-
-
+2
-
